The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
TD-1792 is compared to vancomycin for the treatment of cSSSI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
203
TD-1792 2 mg/kg/day IV
Vancomycin 1 Gm IV q 12 hrs
Allan Churukian
National City, California, United States
Clinical response
Time frame: 7 to 14 days after last antibiotic dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.